Background The clinical manifestation of hepatocellular carcinoma (HCC) with hepatitis B virus (HBV) varies significantly between patients treated with or without nucleos(t) ide analog (NUC) therapy. To have a better understanding of HCC with HBV, we compared the clinical features of patients with HCC receiving or not receiving NUC therapy. Methods We retrospectively reviewed the medical records of 76 patients with HBV-caused HCC who received treatment at the Hunan Provincial Peoples’ Hospital starting from January 1, 2008 to December 31, 2017. They were categorized into two groups, namely, NUC group and non-NUC group, based on whether they had received NUC therapy or not. Results The percentage of liver pain (36.36% vs. 79.07%; p < 0.05) and appetite loss (30.30% vs. 70.27%; p < 0.05) in the NUC group was lower than that in the non-NUC group. We observed a similar trend for the percentage of undetectable HBV-DNA (11.63% vs. 63.64%; p < 0.05) and normal ALT (25.58% vs. 75.76%; p < 0.05) between non-NUC and NUC groups. There were no significant differences between the two groups with respect to TBiL ( p = 0.370) and ALB ( p = 0.475). The same trend was observed for the proportion of HBeAg negative ( p = 0.719) and AFP ≤ 14.65 ng/mL ( p = 0.199) in both groups. Single tumor nodule was more common in the NUC group compared to the non-NUC group (66.67% vs. 6.98%; p < 0.05). An opposite trend was observed for portal vein invasion (18.18% vs. 79.07%; p < 0.05) and metastasis (0% vs. 44.19%; p < 0.05). Conclusions Nucleos(t) ide analog therapy exerts a significant impact on the clinical and radiological characteristics of hepatocellular carcinoma with HBV. Patients receiving nucleos(t) ide analog therapy were found to have milder symptoms and fewer radiographic findings.

中文翻译：

---

Nucleos(t) ide 类似物治疗患者肝细胞癌伴乙型肝炎病毒的临床特征

背景 乙型肝炎病毒 (HBV) 肝细胞癌 (HCC) 的临床表现在接受或不接受核苷（酸）类似物 (NUC) 治疗的患者之间存在显着差异。为了更好地了解 HCC 与 HBV，我们比较了接受或未接受 NUC 治疗的 HCC 患者的临床特征。方-NUC 组，根据他们是否接受过 NUC 治疗。结果肝痛（36.36% vs. 79.07%；p < 0.05）和食欲减退（30.30% vs. 70.27%；p < 0. 05) NUC 组低于非 NUC 组。我们观察到非 NUC 组和 NUC 组之间无法检测到的 HBV-DNA 百分比（11.63% 对 63.64%；p < 0.05）和正常 ALT（25.58% 对 75.76%；p < 0.05）的百分比趋势相似。两组在 TBiL (p = 0.370) 和 ALB (p = 0.475) 方面没有显着差异。两组中 HBeAg 阴性 (p = 0.719) 和 AFP ≤ 14.65 ng/mL (p = 0.199) 的比例趋势相同。与非 NUC 组相比，NUC 组的单个肿瘤结节更常见（66.67% 对 6.98%；p < 0.05）。门静脉侵犯（18.18% vs. 79.07%；p < 0.05）和转移（0% vs. 44.19%；p < 0.05）观察到相反的趋势。结论 Nucleos(t) ide 类似物治疗对乙型肝炎肝细胞癌的临床和放射学特征有显着影响。接受核苷(t) ide 类似物治疗的患者被发现症状较轻，影像学检查结果较少。